Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.

Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.3579.2019. doi: 10.1158/1078-0432.CCR-19-3579. [Epub ahead of print]

2.

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.

Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV.

Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30.

PMID:
32007138
3.

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martinez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A.

Cancer Treat Rev. 2020 Mar;84:101965. doi: 10.1016/j.ctrv.2020.101965. Epub 2020 Jan 17.

PMID:
32000054
4.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2019 Nov 1;30(11):1846. doi: 10.1093/annonc/mdz219. No abstract available.

PMID:
31407000
5.

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. No abstract available.

6.

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E.

Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407. Epub 2019 Jan 24.

7.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

8.

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.

Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647.

9.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1434.

10.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2017 Jun 1;28(6):1309-1315. doi: 10.1093/annonc/mdx078. Erratum in: Ann Oncol. 2019 Nov 1;30(11):1846. Ann Oncol. 2019 Nov;30(11):1846.

11.

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C.

JAMA Oncol. 2017 Feb 1;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824. Erratum in: JAMA Oncol. 2019 Jan 1;5(1):122.

12.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res Treat. 2016 Feb;156(1):81-9. doi: 10.1007/s10549-016-3725-z. Epub 2016 Feb 24.

13.

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S.

J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.

PMID:
25534375
14.

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.

Pharmacoeconomics. 2015 Feb;33(2):179-90. doi: 10.1007/s40273-014-0227-x.

15.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.

Virchows Arch. 2014 Oct;465(4):409-17. doi: 10.1007/s00428-014-1652-0. Epub 2014 Sep 14.

16.

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, Ruiz A, Weber KE, Munarriz B, Petry C, Rodriguez CA, Kronenwett R, Crespo C, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res. 2014 Apr 12;16(2):R38. doi: 10.1186/bcr3642.

17.

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.

18.

ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.

Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, Lehrach H, Schweiger MR, Sültmann H.

PLoS One. 2013;8(3):e59976. doi: 10.1371/journal.pone.0059976. Epub 2013 Mar 29.

19.

A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.

Hellwinkel OJ, Sellier C, Sylvester YM, Brase JC, Isbarn H, Erbersdobler A, Steuber T, Sültmann H, Schlomm T, Wagner C.

Int J Mol Sci. 2013 Mar 4;14(3):5239-49. doi: 10.3390/ijms14035239.

20.

Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.

Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann H, Muley T, Kuner R.

Lung Cancer. 2013 May;80(2):223-7. doi: 10.1016/j.lungcan.2013.01.013. Epub 2013 Feb 11.

PMID:
23410826
21.

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.

Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M.

Breast Cancer Res. 2013 Feb 7;15(1):R11. doi: 10.1186/bcr3384.

22.

Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia.

Jarius S, Martínez-García P, Hernandez AL, Brase JC, Borowski K, Regula JU, Meinck HM, Stöcker W, Wildemann B, Wandinger KP.

J Neuroinflammation. 2013 Jan 15;10:7. doi: 10.1186/1742-2094-10-7.

23.

From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.

Brase JC, Kronenwett R, Petry C, Denkert C, Schmidt M.

Microarrays (Basel). 2013 Aug 29;2(3):243-64. doi: 10.3390/microarrays2030243. Review.

24.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.

25.

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.

Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M, Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Müller BM, Schmidt M, Filipits M, Dubsky P, Petry C, Dietel M, Denkert C.

BMC Cancer. 2012 Oct 5;12:456. doi: 10.1186/1471-2407-12-456.

26.

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.

27.

The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.

Kuner R, Fälth M, Pressinotti NC, Brase JC, Puig SB, Metzger J, Gade S, Schäfer G, Bartsch G, Steiner E, Klocker H, Sültmann H.

J Mol Med (Berl). 2013 Feb;91(2):237-48. doi: 10.1007/s00109-012-0949-1. Epub 2012 Sep 4.

PMID:
22945237
28.

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR.

Cancer Discov. 2012 Nov;2(11):1024-35. doi: 10.1158/2159-8290.CD-12-0041. Epub 2012 Aug 28.

29.

microRNA biomarkers in body fluids of prostate cancer patients.

Kuner R, Brase JC, Sültmann H, Wuttig D.

Methods. 2013 Jan;59(1):132-7. doi: 10.1016/j.ymeth.2012.05.004. Epub 2012 May 29.

PMID:
22652624
30.

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.

Müller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, Prinzler J, Kronenwett R, Dietel M, Denkert C.

J Clin Pathol. 2012 Jul;65(7):660-2. doi: 10.1136/jclinpath-2012-200716. Epub 2012 Mar 23.

31.

Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.

Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf TH, Balabanov S.

J Proteome Res. 2012 Apr 6;11(4):2452-66. doi: 10.1021/pr201172n. Epub 2012 Mar 28.

PMID:
22424448
32.

Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer.

Gade S, Porzelius C, Fälth M, Brase JC, Wuttig D, Kuner R, Binder H, Sültmann H, Beissbarth T.

BMC Bioinformatics. 2011 Dec 21;12:488. doi: 10.1186/1471-2105-12-488.

33.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

34.

Antibody-mediated signal amplification for reverse phase protein array-based protein quantification.

Brase JC, Mannsperger H, Sültmann H, Korf U.

Methods Mol Biol. 2011;785:55-64. doi: 10.1007/978-1-61779-286-1_5.

PMID:
21901593
35.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T.

Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26.

36.

Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage.

Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, Moldenhauer G, Marmé F, Sültmann H, Altevogt P.

Gynecol Oncol. 2011 Aug;122(2):437-46. doi: 10.1016/j.ygyno.2011.04.035. Epub 2011 May 20.

PMID:
21601258
37.

Serum microRNAs as non-invasive biomarkers for cancer.

Brase JC, Wuttig D, Kuner R, Sültmann H.

Mol Cancer. 2010 Nov 26;9:306. doi: 10.1186/1476-4598-9-306. Review.

38.

Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients.

Johannes M, Brase JC, Fröhlich H, Gade S, Gehrmann M, Fälth M, Sültmann H, Beissbarth T.

Bioinformatics. 2010 Sep 1;26(17):2136-44. doi: 10.1093/bioinformatics/btq345. Epub 2010 Jun 30.

PMID:
20591905
39.

Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification.

Brase JC, Mannsperger H, Fröhlich H, Gade S, Schmidt C, Wiemann S, Beissbarth T, Schlomm T, Sültmann H, Korf U.

Proteome Sci. 2010 Jun 22;8:36. doi: 10.1186/1477-5956-8-36.

40.

Circulating miRNAs are correlated with tumor progression in prostate cancer.

Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H.

Int J Cancer. 2011 Feb 1;128(3):608-16. doi: 10.1002/ijc.25376.

41.

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.

Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6.

42.

Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?

Gehrmann M, Schmidt M, Brase JC, Roos P, Hengstler JG.

Pharmacogenomics. 2008 Jul;9(7):969-74. doi: 10.2217/14622416.9.7.969.

PMID:
18597657

Supplemental Content

Loading ...
Support Center